Vivid Mercant EPS has decreased to Rs. 0.01 in March 2025 from Rs. 9.64 in March 2024. Vivid Mercant shares closed at 7.05 on June 23, 2025 (BSE) and has given 18.09% returns over the last 6 ...

More than 80% of Omvoh responders from the VIVID-1 study maintained endoscopic response at week 104 in VIVID-2. Endoscopic and clinical remission were maintained by 72.5% and 86.9%, respectively.

VIVID-2 Clinical Trial (ClinicalTrials.gov identifier: NCT04232553) What You Need to Know. VIVID-2 is an ongoing open-label extension study designed to evaluate the long-term efficacy and safety ...

In VIVID-2, the long-term safety profile of Omvoh in patients with moderately to severely active Crohn's disease was generally consistent with the known safety profile of Omvoh. During the second year ...

On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz). In January, the FDA approved Omvoh for moderately to severely ...